Literature DB >> 2146981

Cell membrane expression and functional role of the p75 subunit of interleukin-2 receptor in lymphoproliferative disease of granular lymphocytes.

R Zambello1, L Trentin, G Pizzolo, P Bulian, M Masciarelli, C Feruglio, C Agostini, R Raimondi, T Chisesi, G Semenzato.   

Abstract

The cell membrane expression and functional role of the interleukin-2 receptor (IL-2R) was analyzed in nine patients with lymphoproliferative disease of granular lymphocytes (LDGL) using monoclonal antibodies (MoAbs) specific for the p75 (TU27) and the p55 (anti-Tac) subunits of IL-2R. Four patients were characterized by the proliferation of CD3+CD8+ granular lymphocytes (GL) expressing the alpha/beta T-cell receptor (T alpha beta) and one case by the proliferation of CD3+CD4-CD8- GL expressing the gamma/delta T-cell receptor (T gamma delta); in four additional cases proliferating cells were CD3 negative GL. Consistent with data observed on normal GL, phenotypic analysis demonstrated that patients' GL lack the expression of the p55 IL-2R, whereas the p75 subunit is constitutionally expressed by expanding GL of both T-cell (either T alpha beta and T gamma delta) and natural killer (NK) origin in variable proportions (11% to 94% of cells). The analysis of the cytotoxic and proliferative activity demonstrated that the anti-p55 MoAb failed to inhibit IL-2-mediated activation, whereas a marked inhibition of both cytotoxicity and proliferation were obtained using the anti-p75 chain specific MoAb. These data indicate that the p75 chain of IL-2R is responsible for IL-2 signal transduction in both CD3+ and CD3- LDGL patients' GL.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2146981

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  7 in total

1.  Preclinical and phase I clinical trial of blockade of IL-15 using Mikbeta1 monoclonal antibody in T cell large granular lymphocyte leukemia.

Authors:  John C Morris; John E Janik; Jeffrey D White; Thomas A Fleisher; Margaret Brown; Mitsuru Tsudo; Carolyn K Goldman; Bonita Bryant; Michael Petrus; Lois Top; Cathryn C Lee; Wendy Gao; Thomas A Waldmann
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-30       Impact factor: 11.205

2.  Coexpression of Fc gamma receptor IIIA and interleukin-2 receptor beta chain by a subset of human CD3+/CD8+/CD11b+ lymphocytes.

Authors:  S Zupo; L Azzoni; R Massara; A D'Amato; B Perussia; M Ferrarini
Journal:  J Clin Immunol       Date:  1993-05       Impact factor: 8.317

3.  Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression.

Authors:  P K Epling-Burnette; J H Liu; R Catlett-Falcone; J Turkson; M Oshiro; R Kothapalli; Y Li; J M Wang; H F Yang-Yen; J Karras; R Jove; T P Loughran
Journal:  J Clin Invest       Date:  2001-02       Impact factor: 14.808

4.  Expression of a functional p75 interleukin-2 receptor on lung lymphocytes from patients with human immunodeficiency virus type 1 (HIV-1) infection.

Authors:  R Zambello; L Trentin; R Benetti; A Cipriani; C Crivellaro; P Cadrobbi; C Agostini; G Semenzato
Journal:  J Clin Immunol       Date:  1992-09       Impact factor: 8.317

5.  Detection of monoclonal T populations in patients with KIR-restricted chronic lymphoproliferative disorder of NK cells.

Authors:  Cristina Gattazzo; Antonella Teramo; Francesca Passeri; Elena De March; Samuela Carraro; Valentina Trimarco; Federica Frezzato; Tamara Berno; Gregorio Barilà; Veronica Martini; Francesco Piazza; Livio Trentin; Monica Facco; Gianpietro Semenzato; Renato Zambello
Journal:  Haematologica       Date:  2014-09-05       Impact factor: 9.941

6.  Functional role of IL-2 receptors on tumour-infiltrating lymphocytes.

Authors:  L Trentin; R Zambello; P Bulian; A Cerutti; A Milani; E Pirone; D Nitti; C Agostini; G Semenzato
Journal:  Br J Cancer       Date:  1994-06       Impact factor: 7.640

7.  Tumour-infiltrating lymphocytes bear the 75 kDa tumour necrosis factor receptor.

Authors:  L Trentin; R Zambello; P Bulian; A Cerutti; C Enthammer; M Cassatella; D Nitti; M Lise; C Agostini; G Semenzato
Journal:  Br J Cancer       Date:  1995-02       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.